IL6R and Burkitt lymphoma: Recently, miR-197 was found to act synergistically with EBV-BART6-3p to reduce the expression of IL-6R, thereby compromising host immune defense in EBV-positive Burkitt Lymphoma (Zhang et al., 2017).